<DOC>
	<DOCNO>NCT02574728</DOCNO>
	<brief_summary>This study aim determine efficacy daily sirolimus celecoxib , low dose etoposide alternate cyclophosphamide pediatric participant relapse refractory tumor .</brief_summary>
	<brief_title>Sirolimus Combination With Metronomic Chemotherapy Children With Recurrent and/or Refractory Solid CNS Tumors</brief_title>
	<detailed_description>This study aim learn combination oral sirolimus daily celecoxib , oral etoposide alternate every 21 day oral cyclophosphamide ( metronomic chemotherapy ) effective shrink relapsed refractory tumor pediatric participant . In addition , study seek learn length time combination keep tumor growing , learn side effect sirolimus use combination , learn sirolimus work evaluate blood tumor tissue .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Participants follow tumor experience relapse follow frontline therapy , refractory frontline therapy , participant tumor carry poor prognosis know standard curative therapy Brain tumor World Health Organization ( WHO ) grade Extracranial solid tumor include neuroblastoma Bone tumor ( osteosarcoma , Ewing sarcoma ) Rhabdomyosarcoma Soft tissue sarcoma Wilms tumor Other rare solid tumor Participants must histologic verification malignancy original diagnosis relapse , except participant intrinsic brain stem tumor , optic pathway glioma , participant pineal tumor elevation serum cerebrospinal fluid ( CSF ) alphafetoprotein ( AFP ) betaHCG ( betahuman chorionic gonadotropin ) . Karnofsky performance level great equal 50 percent participant great 16 year age time screen Lansky performance level great equal 50 percent participant less equal 16 year age time screen Fully recover acute toxic effect prior anticancer therapy Adequate bone marrow function deem protocol time screen Adequate renal function deem study protocol time screen Adequate liver function deem study protocol time screen Adequate pulmonary function deem study protocol time screen Women currently pregnant breastfeed Receiving corticosteroid stable dose least 7 day Currently receive enzyme induce anticonvulsant Currently receive receive potent CYP3A4 ( enzyme ) inducer inhibitor Currently receive another investigational drug Currently receive anticancer agent Uncontrolled infection Participants opinion investigator may able comply safety monitoring requirement</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pediatrics</keyword>
	<keyword>Brain Tumors</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Ewing 's Sarcoma</keyword>
	<keyword>Rhabdomyosarcoma</keyword>
	<keyword>Wilms Tumors</keyword>
	<keyword>Soft Tissue Sarcomas</keyword>
</DOC>